Christopher Sweeney
Dana Farber Cancer Institute, MA, United States
Dr. Sweeney is a Medical Oncologist at the Dana-Farber Cancer Institute (MA, USA) and Professor of Medicine at Harvard Medical School. In late 2021, he will return to Australia to be Director of South Australian Immunogenomics Cancer Institute (SAIGENCI) at University of Adelaide.
He received his medical degree from the University of Adelaide (Australia) and completed an internship at the Royal Adelaide Hospital (Australia). Dr. Sweeney did his residency in internal medicine at Gundersen Lutheran Medical Center (WI, USA) and a fellowship in hematology/oncology at Indiana University Medical Center (IN, USA), where he was later appointed Associate Director for Clinical Research for the Simon Cancer Center. Dr. Sweeney joined the Lank Center for Genitourinary Oncology at DFCI and Harvard Medical School (MA, USA) in 2009.
His primary research interest is drug discovery and development. His academic focus is primarily on the management of genitourinary malignancies, with a focus on prostate and testicular cancer.
Presentations this author is a contributor to:
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD (ANZUP 1303) (#273)
3:00 PM
Scott G Williams
Posters1
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304) (#269)
3:00 PM
Ian Davis
Posters1